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Abstract
Background: The treatment schedules for stereotactic body radiotherapy (SBRT) for lung cancer vary from
institution to institution. Several reports have indicated that stage IB patients had worse outcomes than stage IA
patients when the same dose was used. We evaluated the clinical outcomes of SBRT for stage I non-small cell lung
cancer (NSCLC) treated with different doses depending on tumor diameter.
Methods: Between February 2004 and November 2008, 124 patients with stage I NSCLC underwent SBRT. Total
doses of 44, 48, and 52 Gy were administered for tumors with a longest diameter of less than 1.5 cm, 1.5-3 cm,
and larger than 3 cm, respectively. All doses were given in 4 fractions.
Results: For all 124 patients, overall survival was 71%, cause-specific survival was 87%, progression-free survival was
60%, and local control was 80%, at 3 years. The 3-year overall survival was 79% for 85 stage IA patients treated
with 48 Gy and 56% for 37 stage IB patients treated with 52 Gy (p = 0.05). At 3 years, cause-specific survival was
91% for the former group and 79% for the latter (p = 0.18), and progression-free survival was 62% versus 54% (p =
0.30). The 3-year local control rate was 81% versus 74% (p = 0.35). The cumulative incidence of grade 2 or 3
radiation pneumonitis was 11% in stage IA patients and 30% in stage IB patients (p = 0.02).
Conclusions: There was no difference in local control between stage IA and IB tumors despite the difference in
tumor size. The benefit of increasing the SBRT dose for larger tumors should be investigated further.
Background
Stereotactic body radiotherapy (SBRT) for lung tumors
was introduced in the mid 1990s [1], and it has been
performed in many institutions as a new treatment
modality for stage I primary lung cancer and oligometa-
static lung cancer. Promising clinical results have been
reported despite the use of various treatment protocols
[2-9]. According to a recently published survey of SBRT
in Japan, the treatment techniques and schedules
applied for SBRT for lung cancer varied greatly from
institution to institution [10]. The most frequently used
schedule was 48 Gy in 4 fractions for both stage IA and
IB primary lung cancer and metastatic lung cancer.
As a result, it was found that the outcomes of stage IB
patients were worse than those of stage IA patients at the
same dose [3-5], which suggests that SBRT doses should
be adjusted according to tumor size. We have performed
SBRT for lung tumors since 2004 and changed the pre-
scribed dose depending on tumor diameter. In this study,
we report the clinical outcomes of SBRT performed with
our prospective hypothesis-driven protocol.
Methods
Eligibility Criteria
The eligibility criteria were as follows: histologically-
confirmed non-small cell lung cancer (NSCLC)
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diagnosed as T1N0M0 or T2N0M0 stage according to
the International Union Against Cancer 1997 system
by CT of the chest and upper abdomen, bone scinti-
graphy, and brain magnetic resonance imaging and a
World Health Organization performance status ≤ 2.
When 18-fluoro-deoxyglucose-positron emission tomo-
graphy (FDG-PET) was performed, bone scintigraphy
was omitted. Even when the diagnosis of NSCLC could
not be confirmed with transbronchial lung biopsy or
CT-guided biopsy, such cases were included in the
study if FDG-PET findings were positive and the
tumor increased in size during the observation period.
No restrictions were imposed with regard to the tumor
location. Any patients who had undergone prior ther-
apy were excluded. All patients consented to the treat-
ment after they had been informed of the method and
rationale of the study.
Patient Characteristics
Between February 2004 and November 2008, 124
patients underwent SBRT for NSCLC. Eighty-four were
men and 40 were women. The age at SBRT ranged
from 26 to 89 years, with a median of 77 years. The
tumor diameter ranged from 12 to 55 mm with a
median of 27 mm. In 10 patients, NSCLC could not be
histologically proven. The patient characteristics are
summarized in Table 1.
Treatment methods
Our methods for immobilization and treatment planning
were described in detail previously [11]. We used the
BodyFIX system (Medical Intelligence, Schwab-
muenchen, Germany) for patient immobilization. CT
images for treatment planning were obtained under nor-
mal breathing, and with breath holding during the
expiratory and inspiratory phases. The clinical target
volume (CTV) was defined as the visible gross tumor
volume (GTV). The CTV on CT during the 3 phases
were superimposed on a 3-dimensional radiation treat-
ment planning system (Eclipse Version 7.5.14.3, Varian
Medical Systems, Palo Alto, California, USA) to repre-
sent the internal target volume (ITV). We defined the
planning target volume (PTV) margin for the ITV as
5 mm in the lateral and anteroposterior directions and
10 mm in the craniocaudal direction. Three coplanar
and 4 noncoplanar static ports were used. SBRT was
delivered by a linear accelerator (CLINAC 23EX, Varian
Medical Systems, Palo Alto, California, USA) with 6-MV
Table 1 Patient characteristics
Stage IA Stage IB
Prescribed dose (in 4 fractions) All 44 Gy 48 Gy 52 Gy
Patient number 124 2 85 37
Age (years)
Range (median) 29-89 (77) 67, 70 58-87 (77) 29-89 (78)
Gender
Male 84 1 54 29
Female 40 1 31 8
Performance status
0 65 2 47 16
1 48 0 31 17
2 11 0 7 4
Tumor size (mm)
Range (median) 12-55 (27) 12, 14 15-34 (24) 31-55 (35)
Operability
Operable 40 2 27 11
Non-operable 84 0 58 26
Histology
Adenocarcinoma 66 2 46 18
Squamous cell carcinoma 35 0 19 16
Unclassified NSCLC 13 0 10 3
Unproven 10 0 10 0
Tumor location
Central 29 0 18 11
Peripheral 95 2 67 26
Abbreviations: NSCLC = non-small cell lung cancer.
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photons. The treatment was performed twice a week.
The median treatment period was 11 days.
Prescription dose
The dose was prescribed according to the tumor dia-
meter. The planned dose was 44 Gy in 4 fractions for
tumors with a maximum diameter of less than 1.5 cm,
48 Gy in 4 fractions for tumors with a maximum dia-
meter of 1.5-3 cm, and 52 Gy in 4 fractions for those
with a maximum diameter larger than 3 cm. Assuming
an a/b ratio of 10 Gy, the biological effective dose
(BED) was 92 Gy for the 44-Gy schedule, 106 Gy for
the 48-Gy schedule, and 120 Gy for the 52-Gy schedule.
However, the BED must be cautiously used in these
dose-fractionation ranges [12]. Pencil beam convolution
with Batho power law correction of the Eclipse system
was used as the dose calculation algorithm. The pre-
scribed dose represented that delivered to the isocenter,
and it was ensured that 95% of the PTV received at
least 80% of the prescribed isocenter dose. Dose con-
straints were set for the spinal cord, and only one of the
beams was allowed to pass the spinal cord.
Evaluation
For follow-up after SBRT, chest CT was performed at 2-
month intervals until 6th months, and every 2 to 4
months thereafter. FDG-PET was performed whenever
necessary. Local recurrence was suspected when enlar-
gement of a consolidated fibrotic mass was detected on
CT images without signs of inflammation and was diag-
nosed by high uptake on FDG-PET (standardized uptake
value > 5) and/or biopsy. Local recurrence was con-
firmed by biopsy in 2 patients. Toxicity was evaluated
using the Common Terminology Criteria for Adverse
Events Version 3. Grade 2 radiation pneumonitis was
defined as symptomatic but not interfering with activ-
ities of daily life.
Statistical Analysis
The unpaired t-test or the Mann-Whitney U test was
used to compare the characteristics of the patients. Sur-
vival rates and cumulative incidences of complications
were calculated by the Kaplan-Meier method from the
start of SBRT. The log-rank test was used to compare
the control and survival rates between the subsets. Sta-
tistical analysis was carried out using StatView software
version 5.0 (SAS Institute, Cary, NC).
Results
Survival
Among 124 NSCLC patients treated with SBRT, 87 had
stage IA and 37 had stage IB disease. Two stage IA
patients with tumors of less than 1.5 cm in diameter
were treated with 44 Gy in 4 fractions, and 85 patients
with larger T1 tumors were treated with 48 Gy in 4
fractions. All 37 stage IB patients were treated with 52
Gy in 4 fractions. There were no significant differences
in the distribution of age (p = 0.95), gender (p = 0.11),
PS (p = 0.26), operability (p = 0.82), histology (p = 0.71),
or tumor location (p = 0.31) between the 85 stage IA
patients treated with 48 Gy in 4 fractions and the 37
stage IB patients. The median follow-up period for living
patients was 26 months (range: 7 to 66 months). Local
recurrence developed in 18 patients (11 among the stage
IA patients and 7 among the stage IB patients). Regional
lymph node recurrence occurred in 19 patients (10
among the stage IA patients and 9 among the stage IB
patients). Distant metastases appeared in 25 patients (16
among the stage IA patients and 9 among the stage IB
patients).
For all 124 patients, the overall survival (OAS) rate
was 71%, the cause-specific survival (CSS) rate was 87%,
and the progression-free survival (PFS) rate was 60% at
3 years (Figure 1). The 3-year OAS was 79% for the 85
stage IA patients treated with 48 Gy in 4 fractions and
56% for the 37 stage IB patients (p = 0.05). The 3-year
CSS was 91% for the former group and 79% for the lat-
ter (p = 0.18). The 3-year PFS was 62% versus 54% (p =
0.30). The 3-year local control rate was 80% for all
patients, and it was 81% for the stage IA patients treated
with 48 Gy and 74% for the stage IB patients, with no
significant difference between them (p = 0.35). Two
stage IA patients treated with 44 Gy in 4 fractions were
alive without recurrence at 21 and 14 months,
respectively.
Treatment outcomes were also analyzed with respect
to the tumor location [13]. The 3-year OAS was 72% for
patients with tumors in the central (perihilar or central
mediastinal) region and 71% for those with tumors in
the peripheral region (p = 0.63). The 3-year CSS was
82% for patients with central tumors and 89% for
patients with peripheral tumors (p = 0.63). The 3-year
PFS was 52% versus 62% (p = 0.79), and the 3-year local
control was 66% versus 83% (p = 0.33).
Toxicities
Grade 1, 2, and 3 radiation pneumonitis was observed in
66, 17, and 2 patients, respectively. At 3 years, the
cumulative incidence of grade 2 or 3 pneumonitis was
16%, and it was 11% for stage IA patients treated with
48 Gy in 4 fractions and 30% for stage IB patients trea-
ted with 52 Gy in 4 fractions (p = 0.02). Other adverse
events were as follows: grade 2 esophagitis was seen in 3
patients, grade 1 and 3 pleural effusion were detected in
23 and 1 patient(s), respectively; grade 1 atelectasis was
found in 6 patients; grade 1 pneumothorax was detected
in 3 patients; grade 1 and 2 dermatitis were observed in
7 and 6 patients, respectively; grade 1 and 2 rib fractures
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were seen in 7 and 1 patient(s), respectively; grade 1 soft
tissue swelling was detected in 6 patients; and grade 2
cardiac muscle damage and effusion were detected in 1
patient each. At 3 years, the cumulative incidence of
grade 2 or 3 radiation pneumonitis was 25% in patients
with central tumors and 13% in patients with peripheral
tumors (p = 0.11).
Discussion
Following the excellent clinical outcomes reported by
Nagata et al. [2], the most frequently used schedule for
SBRT for NSCLC in Japan has been 48 Gy in 4 fractions
for both stage IA and IB tumors [10]. However, other
investigators reported worse outcomes in stage IB
patients when the same fractionation schedule was used
[3-5]. Their protocols are summarized in Table 2. Oni-
maru et al. [3] reported 3-year CSS rates of 88% and
50% for stage IA and IB patients, respectively. Signifi-
cant differences were found in OAS, CSS, and local con-
trol rates between stage IA and IB tumors. Koto et al.
[4] also showed that the 3-year local control rate was
78% and 40% for stage IA and IB, respectively. Baumann
et al. [5] reported that the estimated risk of all failures
was increased in stage IB patients compared with stage
IA patients. Onishi et al. [14] reported the results of a
multi-institutional study. The irradiation schedules of
participating institutions involved total doses of 30 to 84
Gy (at the isocenter) delivered in 1 to 14 fractions.
Although the treatment protocols varied greatly, the 5-
year OAS rate in operable groups receiving a sufficient
dose was better in stage IA than in stage IB patients. In
general, greater doses are needed to control larger
tumors in conventional radiotherapy [15-17]. The
above-mentioned results suggest that the control rates
for stage IB tumors should be lower than those for stage
IA tumors at the same dose. On the other hand, smaller
doses could be sufficient for controlling smaller tumors.
Takeda et al. [6] also administered the same dose and
achieved favorable outcomes in both stage IA and IB
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Figure 1 Curves for (a) overall survival, (b) cause-specific survival, (c) progression-free survival, and (d) local control in stage I NSCLC
patients. Solid line, all patients (n = 124); dashed line, stage IA patients treated with 48 Gy in 4 fractions (n = 85); and dotted line, stage IB
patients treated with 52 Gy in 4 fractions (n = 37).
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administered in a certain number of fractions, stage IB
tumors can be controlled as well as stage IA tumors.
One study by Fakris et al. [7] prescribed a greater dose
for stage IB tumors than for stage IA (Table 2), and
they reported no significant difference in median survi-
val or 3-year CSS between stages IA and IB. We also
prescribed a greater dose for stage IB tumors. The CSS,
PFS, and local control rates for stage IB patients were
not significantly different from those for stage IA
patients.
The local control rates in our study do not seem to be
high enough compared with the rates in other recent
reports [5-7,18]. In particular, a recent Radiation Ther-
apy Oncology Group study obtained a 3-year local con-
trol rate of 97.6% using 54 Gy in 3 fractions delivered to
the periphery of the PTV [18]. Guckenberger et al. [19]
indicated a dose-response relationship for local control
in pulmonary SBRT. Our doses might have been insuffi-
cient for local control in a certain proportion of
patients. We delivered the dose to the isocenter using
Pencil beam convolution with Batho power law correc-
tion, and we ensured that 95% of the PTV received at
least 80% of the prescribed dose. However, the dose dis-
tribution at the PTV periphery might have been insuffi-
cient [6,20]. We think it is necessary to use a more
accurate inhomogeneity correction algorithm to improve
dose conformality. It might also be argued that only
using 7 beams resulted in inferior dose conformality
compared to using more beams. However, in our ana-
lyses before this study, 7 beams were considered accep-
table. Indeed, the mean V20 (volume of lung minus
GTV receiving ≥ 20 Gy: 6.7% ± 2.9% [SD]) and the
mean lung dose (MLD: 4.5 ± 1.5 Gy [SD]) for all
patients in the present study were not inferior to those
reported by other investigators [21-23].
Since greater doses were prescribed to a larger PTV,
the normal tissues around the PTV absorbed greater
doses, which may have increased toxicities in normal
organs. Radiation pneumonitis is the most significant
dose-related toxicity. Some dose-volume parameters
such as the V20 and MLD are reported to correlate
with radiation pneumonitis [24,25]. Takeda et al. [21]
reported a linear correlation between tumor diameter
and V20 in SBRT. The mean PTV (± SD) of tumors
irradiated with 48 Gy and 52 Gy in 4 fractions was 45 ±
21 cm3 and 78 ± 25 cm3, respectively (p < 0.0001). So,
the PTV of stage IB tumors was significantly larger than
that of stage IA tumors. The V 20 was 5.9% ± 2.3% for
the 48-Gy group and 8.4% ± 3.5% for the 52-Gy group
(p < 0.0001), and the MLD were 4.1 ± 1.2 Gy and 5.4 ±
1.8 Gy, respectively (p < 0.0001). These data indicate
that a greater dose was absorbed in the normal lung.
This was considered to have caused the significantly
higher cumulative incidence of grade 2 or 3 radiation
pneumonitis in the stage IB patients treated with 52 Gy
in 4 fractions compared with that of the stage IA
patients treated with 48 Gy in 4 fractions in our study.
A dose-response relationship for radiation-induced
pneumonitis after SBRT has also been reported recently
[22,23].
Various dose fractionation schedules have been used
in SBRT for lung cancers [26], and optimum schedules
have been sought. A future topic for study is dose esca-
lation, and another is to combine SBRT with che-
motherapy to improve outcomes. The Japan Clinical
Oncology Group is conducting a dose escalation study
for stage IB NSCLC. Stage IB tumors are not only diffi-
cult to control, but are also associated with more occult
distant metastases than stage IA tumors. So, combined
chemotherapy could be effective. Chen et al. [27]
Table 2 Protocols for stage IA and IB NSCLC
First author (Ref) Prescribed dose
(Gy/fraction)
Reference point Isocenter dose (Gy/fraction) Calculation algorithm/inhomogeneity correction
Nagata (2) 48/4 isocenter 48/4 PBC
/yes
Onimaru (3) 40 or 48/4 isocenter 40 or 48/4 Clarkson or superposition
/yes
Koto (4) 45/3 or 60/8 isocenter 45/3 or 60/8 BPL
/yes
Baumann (5) 45/3 67% at PTV periphery 67.2/3 PBC
/yes














* = for stage IA, ** = for stage IB.
Abbreviations: PBC = Pencil beam convolution; BPL = Batho power law; MG = Multigrid.
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demonstrated that SBRT followed by adjuvant che-
motherapy improved OAS. In our protocol, the toxici-
ties associated with stage IA tumors were mild, so it
seems possible that dose escalation for stage IA tumors
would improve local control and survival rates. Most
patients with stage IB tumors are elderly or medically
inoperable, and dose escalation with more conformal
approaches should be investigated for such patients. On
the other hand, considering the relatively high pulmon-
ary toxicities observed in our stage IB patients, com-
bined chemotherapy might be a future strategy for
improving the survival of medically operable stage IB
patients.
Conclusions
A protocol involving 44, 48, or 52 Gy being delivered in
4 fractions to the isocenter was feasible for patients with
stage IA or IB NSCLC. There was no difference in local
control between stage IA and IB tumors despite the dif-
ference in tumor size. The benefit of increasing the
doses for larger tumors should be investigated further.
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